CaniniL., ChatterjeeA., GuedjJ.A pharmacokinetic/ viral kinetic model to evaluate treatment effectiveness of chronic hepatitis C virus with danoprevir.Antivir Ther2015; 20: 469–477.
2.
GuedjJ., PerelsonA.S.Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.Hepatology2011; 53: 1801–1808.
3.
CaniniL., DebRoyS., MariñoZ.Severity of liver disease affects hepatitis C virus kinetics in patients treated with intravenous silibinin monotherapy.Antivir Ther2015; 20: 149–155.
4.
ConwayJ.M., PerelsonA.S.A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.PLOS Comput Biol2014; 10: e1003769.
